KR960013370A - 트리글리세리드 과다 방지 조성물 - Google Patents

트리글리세리드 과다 방지 조성물 Download PDF

Info

Publication number
KR960013370A
KR960013370A KR1019950034188A KR19950034188A KR960013370A KR 960013370 A KR960013370 A KR 960013370A KR 1019950034188 A KR1019950034188 A KR 1019950034188A KR 19950034188 A KR19950034188 A KR 19950034188A KR 960013370 A KR960013370 A KR 960013370A
Authority
KR
South Korea
Prior art keywords
substituted
group
ring
triglyceride
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019950034188A
Other languages
English (en)
Korean (ko)
Inventor
야스오 스기야마
히데후미 유끼마사
Original Assignee
다께다 구니오
다께다야꾸힝고오교 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다께다 구니오, 다께다야꾸힝고오교 가부시끼가이샤 filed Critical 다께다 구니오
Publication of KR960013370A publication Critical patent/KR960013370A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
KR1019950034188A 1994-10-07 1995-10-06 트리글리세리드 과다 방지 조성물 Ceased KR960013370A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP94-244136 1994-10-07
JP24413694 1994-10-07

Publications (1)

Publication Number Publication Date
KR960013370A true KR960013370A (ko) 1996-05-22

Family

ID=17114301

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950034188A Ceased KR960013370A (ko) 1994-10-07 1995-10-06 트리글리세리드 과다 방지 조성물

Country Status (11)

Country Link
EP (1) EP0705607A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR960013370A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1128657A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU703422B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2160092A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI954773A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUT73422A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO308580B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ280165A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2166320C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW401301B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2231052C (en) * 1995-09-13 2007-11-13 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
EP0862562B1 (en) * 1995-09-13 2001-07-04 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
JPH10513202A (ja) * 1996-06-11 1998-12-15 ゾナジェン，インコーポレイテッド キトサン薬物送達システム
CN1252795A (zh) 1997-04-21 2000-05-10 武田药品工业株式会社 4,1－苯并氧氮杂、它们的类似物和它们作为抑生长素兴奋剂的用途
JP4204657B2 (ja) * 1997-12-05 2009-01-07 有限会社ケムフィズ 糖尿病の予防・治療剤
AU774929B2 (en) 1998-03-31 2004-07-15 Institutes For Pharmaceutical Discovery, Llc, The Substituted indolealkanoic acids
US6207664B1 (en) 1998-11-25 2001-03-27 Pfizer Inc. Squalene synthetase inhibitor agents
TNSN99224A1 (fr) * 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
CA2370141A1 (en) 1999-05-26 2000-12-07 James D. Rodgers 1,4-benzodiazepin-2-ones useful as hiv reverse transcriptase inhibitors
MXPA02001340A (es) * 1999-08-05 2004-07-16 Prescient Neuropharma Inc Compuestos novedosos 1,4-benzodiazepina y derivados de los mismos.
KR20030048465A (ko) * 2000-11-09 2003-06-19 다케다 야쿠힌 고교 가부시키가이샤 고밀도 지질단백질-콜레스테롤 상승제
KR20040100835A (ko) 2001-02-15 2004-12-02 킹 파머슈티칼스 리서치 앤드 디벨로프먼트 아이엔씨 안정된 제약및 갑상선 내분비 호르몬 구성물 및 그제조방법
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
WO2003002147A1 (fr) * 2001-06-28 2003-01-09 Takeda Chemical Industries, Ltd. Medicaments destines a la prevention/au traitement de troubles fonctionnels des organes et du dysfonctionnement des organes
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
EP1591120A4 (en) * 2003-01-28 2009-06-10 Takeda Chemical Industries Ltd RECEPTOR AGONISTS
EP1689383B1 (en) 2003-11-19 2012-10-31 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
MX2007001536A (es) * 2004-08-09 2007-04-02 Takeda Pharmaceutical Agente para disminuir la proteina c reactiva.
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
JP2009512715A (ja) 2005-10-21 2009-03-26 ノバルティス アクチエンゲゼルシャフト レニン阻害剤と抗異脂肪血症剤および／または抗肥満症剤の組み合わせ
BRPI0811204A8 (pt) 2007-05-10 2015-09-22 Bristol Myers Squibb Co Tetra-hidroibenzo-1,4-diazepinas substituídas por arila e heteroarila e uso das mesmas para bloquear a recaptação de norepinefrina, dopamina e serotonina
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
KR102698413B1 (ko) 2020-05-05 2024-08-26 뉴베일런트, 아이엔씨. 헤테로방향족 거대환식 에터 화학치료제
WO2021226208A2 (en) 2020-05-05 2021-11-11 Nuvalent, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents
JP2024537795A (ja) 2021-10-01 2024-10-16 ヌバレント， インク． ヘテロ芳香族大環状エーテル化合物の固体形態、薬学的組成物、及び調製

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180717A (en) * 1988-08-16 1993-01-19 The Upjohn Company Bivalent ligands effective for blocking ACAT enzyme for lowering plasma triglycerides and for elevating HDL cholesterol
FR2659332B1 (fr) * 1990-03-08 1994-04-29 Adit Et Cie Nouvelles pyrrolo [1,2-a] thieno [3,2-f] diazepines [1,4], leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DE69332792T2 (de) * 1992-04-20 2004-01-15 Takeda Chemical Industries Ltd 4,1-Benzoxazepinderivate als Squalen-Synthetase Inhibitoren und ihre Verwendung zur Behandlung von Hypercholesterämie und als Fungizide
CA2099346A1 (en) * 1992-07-17 1994-01-18 Shinji Ohmori Lipid metabolism improving composition
AU678503B2 (en) * 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
WO1995021834A1 (en) * 1994-02-09 1995-08-17 Takeda Chemical Industries, Ltd. Optically active 4,1-benzoxazepine derivatives useful as squalene synthase inhibitors

Also Published As

Publication number Publication date
NZ280165A (en) 1997-07-27
FI954773A7 (fi) 1996-04-08
AU3308195A (en) 1996-04-18
NO953961L (no) 1996-04-09
RU2166320C2 (ru) 2001-05-10
NO308580B1 (no) 2000-10-02
HU9502918D0 (en) 1995-11-28
TW401301B (en) 2000-08-11
CN1128657A (zh) 1996-08-14
HUT73422A (en) 1996-07-29
EP0705607A2 (en) 1996-04-10
CA2160092A1 (en) 1996-04-08
NO953961D0 (no) 1995-10-05
AU703422B2 (en) 1999-03-25
EP0705607A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1996-05-08
FI954773A0 (fi) 1995-10-06

Similar Documents

Publication Publication Date Title
KR960013370A (ko) 트리글리세리드 과다 방지 조성물
RU95117068A (ru) Антигипертриглицеридемическая композиция, способ ее получения, способ лечения или профилактики гипертриглицеридемии, применение соединений
KR970701722A (ko) 포스폰산 디에스테르 유도체(phosphonic diester derivative)
TR200003478T2 (tr) Antikanser maddeleri olarak faydalı izotiyazol türevleri
ATE25974T1 (de) Acyl-substituierte derivate von 1,2,3,4tetrahydroisochinolin-3-carboxysaeuren, ihre salze, diese enthaltende arzneimittel und verfahren zu ihrer herstellung.
BRPI0212346B1 (pt) Compostos derivados de benzotiadiazepina ou um sal farmaceuticamente aceitável do mesmo com efeito inibidor de transporte de ácido de bile ileal, processo para a preparação dos mesmos, uso destes, e, composição farmacêutica.
AU3607895A (en) 1-acyl-4-aliphatylaminopiperidine compounds
ATE176664T1 (de) 2-propylvaleriansäure und 2-propylvalerian- säureamid-derivate und deren verwendung als antikonvulsive mittel
KR940701264A (ko) 안과질환에 대한 마크로라이드 화합물의 용도
BR9201854A (pt) Composto derivado de pridazinas,processo para sua preparacao,e,composicao farmaceutica
KR970707108A (ko) 항염증제로 유용한, 복소환부를 갖는 디-t-부틸페놀 화합물(DI-TERT-BUTYLPHENOL COMPOUNDS WITH HETEROCYCLIC MOIETY, USEFUL AS ANTI-INFLAMMATORY AGENTS)
TR200001140T2 (tr) 6, 11-Köprülü eritromisin türevleri.
DE69429570D1 (de) Galanthamin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente
DE69315699D1 (de) Inhibitoren gegen die aggregation von blutplättchen
ATE81655T1 (de) Cephemverbindungen und verfahren zu ihrer herstellung.
ATE41772T1 (de) Polymethoxybenzyl-piperazin-derivate, verfahren zu ihrer herstellung und diese derivate enthaltende pharmazeutische zusammensetzungen.
DK0804418T3 (da) Platelataggregationshæmmere
FR2707089B1 (fr) Nouveaux dérivés d'acide phosphonique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
KR910004557A (ko) 2,4,6-치환 페놀 유도체
ATE19772T1 (de) Substituierte alpha-(aethyl)-alpha-(phenyl)-(omega-(dialkylami o)-alkoxy)-benzylalkohole, ihre saeureadditionssalze und quaternaeren salze, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel.
DE3870167D1 (de) N-(vinblastinoyl-23)-derivate von 1-aminomethylposphonsaeure, verfahren zu ihrer herstellung und sie enthaltende arzneimittel.
DE69105786D1 (de) Harnstoffderivate, deren Herstellung sowie diese enthaltende pharmazeutische Zusammensetzungen.
ATE149165T1 (de) Stickstoff enthaltende bizyklische derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
ATE5961T1 (de) N-acylpeptid-verbindungen, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
ATE28871T1 (de) Disubstituierte piperidine,verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000